Imeth (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, preventing the formation of tetrahydrofolate needed for purine and pyrimidine synthesis. This halts DNA, RNA and protein production in rapidly dividing cells, producing antiproliferative effects in cancer and immunosuppressive effects in autoimmune disorders.

The specific dose of Imeth is determined by the prescribing clinician based on the patient’s condition, weight, renal function and treatment goals. Dosage regimens vary widely between rheumatologic and oncologic indications, and the prescriber will tailor the schedule to each individual case.

Imeth is classified as Pregnancy Category X, meaning it is contraindicated in pregnancy because it can cause fetal harm. It is also not recommended while breastfeeding, as methotrexate can be excreted in milk and may affect the infant. Effective contraception is required during treatment and for a defined period after discontinuation.

To request Imeth, visit the product page on gnhindia.com, enter the desired quantity, and submit the enquiry form. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if required) and any necessary import documentation.

Imeth is a methotrexate formulation for subcutaneous injection, offering more predictable absorption than oral tablets and often allowing lower total doses. Compared with biologic DMARDs, methotrexate is less costly but may require more laboratory monitoring. Choice of therapy depends on disease severity, patient comorbidities, and treatment response.

Imeth should be stored at 2‑8 °C (refrigerated), protected from light, and must not be frozen or shaken vigorously. Keep the product in its original packaging until use and discard any vial that has been left at room temperature for longer than the manufacturer‑specified time after reconstitution.

Imeth is supplied as a sterile solution for subcutaneous injection. A healthcare professional administers the dose using a pre‑filled syringe or needle‑free device, typically into the abdomen or thigh. The injection site should be rotated to reduce local irritation, and patients should be instructed on proper technique and disposal of sharps.

Serious risks include severe liver toxicity, pulmonary fibrosis, life‑threatening bone marrow suppression, acute renal failure, and severe cutaneous reactions such as Stevens‑Johnson syndrome. Patients should be monitored regularly for signs of organ dysfunction, and any alarming symptoms—such as persistent cough, jaundice, unexplained bruising, or rash—require immediate medical evaluation.

Imeth is contraindicated in pregnant women, individuals with severe hepatic or renal impairment, patients with known hypersensitivity to methotrexate, and those receiving live vaccines. Caution is also advised for patients with pre‑existing lung disease, uncontrolled infections, or significant immunosuppression.